Brent joined Canaan in 1999 as a member of the Kauffman Fellows Program and throughout his tenure has lead investments in an array of healthcare companies, with a focus on biopharma and medtech. Brent’s current investments and board seats include device developer and manufacturer Abyrx, reflux device company EndoGastric Solutions, immune-oncology drug developer Grey Wolf Therapeutics, antibiotic developer Iterum Therapeutics, device maker for chronic back pain Relievant MedSystems, life sciences tool company Unchained Labs, and pain management developer Semnur. His previous companies include Dexcom (DXCM), Revivant (acquired by ZOLL), Peninsula Pharmaceuticals (acquired by JNJ), Cerexa (acquired by FRX), Calixa (acquired by CBST), AtheroMed (acquired by VOLC); Durata Therapeutics (DRTX), Data Sciences International (acquired by HBIO); Elevation Pharmaceuticals (acquired by DNPUF); and Spinifex (acquired by NVS). Prior to joining Canaan, Brent worked in both commercial and technical roles at General Surgical Innovations, Ethicon Endo-Surgery (J&J), and IAP Research. He also has several surgical instrument patents to his credit. Brent earned an M.B.A. from the Tuck School of Business at Dartmouth College after graduating with a B.S. and M.S. in Mechanical Engineering from the University of Dayton.